MARKET

TFFP

TFFP

TFF PHARMACEUTICALS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.44
+0.26
+4.12%
Closed 16:00 07/10 EDT
OPEN
6.23
PREV CLOSE
6.19
HIGH
6.48
LOW
6.00
VOLUME
103.47K
TURNOVER
--
52 WEEK HIGH
6.92
52 WEEK LOW
3.440
MARKET CAP
120.25M
P/E (TTM)
-3.1233
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TFFP stock price target is 13.50 with a high estimate of 15.00 and a low estimate of 12.00.

EPS

TFFP News

More
TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powder
Business Wire · 06/29 14:00
TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder
Business Wire · 06/18 14:00
TFF Pharmaceuticals Receives Orphan Drug Designation For Tacrolimus Inhalation Powder
Benzinga · 06/18 13:07
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 17)
Benzinga · 06/18 12:34
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 06/02 11:45
The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 14)
Benzinga · 05/15 11:49
TFF Pharmaceuticals' (TFFP) CEO Glenn Mattes on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/15 03:26
TFF Pharmaceuticals Reports First Quarter 2020 Financial and Business Results
TFF Pharmaceuticals reports first quarter 2020 financial and business results.
Business Wire · 05/14 20:04

Industry

Biotechnology & Medical Research
-0.39%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Symbol
Price
%Change

About TFFP

TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company. The Company is focused on developing and commercializing drug products based on its Thin Film Freezing (TFF) technology platform. Its TFF platform is designed to enable solubility of poorly water-soluble drugs. Its drug candidates include TFF Vori, TFF Tac-Lac and Triple Combination For chronic obstructive pulmonary disease (COPD)/Asthma. It is developing TFF Vori for the treatment of invasive pulmonary aspergillosis (IPA). TFF Vori is being developed as an inhaled dry powder drug. It is developing TFF Tac-Lac for Immunosuppression to prevent organ transplant rejection. TFF Tac-Lac is being developed as a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. It is also developing a combination dry powder drug intended for use with a dry powder inhaler for the maintenance treatment of bronchospasm associated with moderate to severe COPD.
More

Webull offers kinds of TFF Pharmaceuticals Inc stock information, including NASDAQ:TFFP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TFFP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TFFP stock methods without spending real money on the virtual paper trading platform.